Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Published byHarold Charles Modified over 8 years ago

Similar presentations

Presentation on theme: "Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer."— Presentation transcript:

1 Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer A.Vanden Burgt, BSa, William W. Busse, MDb, Richard J. Martin, MDc, Stanley J. Szefler, MDd, David Donnell, PharmDa Journal of Allergy and Clinical Immunology Volume 106, Issue 6, Pages 1209-1226 (December 2000) DOI: 10.1067/mai.2000.111582 Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

2 Fig. 1 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

3 Fig. 2 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

4 Fig. 3 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

5 Fig. 4 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

6 Fig. 5 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

7 Fig. 6 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

8 Fig. 7 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

9 Fig. 8 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

10 Fig. 9 Journal of Allergy and Clinical Immunology 2000 106, 1209-1226DOI: (10.1067/mai.2000.111582) Copyright © 2000 Mosby, Inc. Terms and Conditions Terms and Conditions

Download ppt "Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer."

Similar presentations

Reducing relative humidity to control the house dust mite Dermatophagoides farinae Larry G. Arlian, PhD, Jacqueline S. Neal, BS, DiAnn L. Vyszenski-Moher,

Reducing relative humidity to control the house dust mite Dermatophagoides farinae Larry G. Arlian, PhD, Jacqueline S. Neal, BS, DiAnn L. Vyszenski-Moher,
W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc 

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc 
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
The editors’ choice Journal of Allergy and Clinical Immunology

The editors’ choice Journal of Allergy and Clinical Immunology
Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.
Asthma and increased bronchial responsiveness in elite athletes: Atopy and sport event as risk factors  Ilkka J. Helenius, MDa, Heikki O. Tikkanen, MDb,

Asthma and increased bronchial responsiveness in elite athletes: Atopy and sport event as risk factors  Ilkka J. Helenius, MDa, Heikki O. Tikkanen, MDb,
Rosa Codina, PhD, Richard F. Lockey, MD 

Rosa Codina, PhD, Richard F. Lockey, MD 
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
Practice Notes from the AAAI

Practice Notes from the AAAI
Badrul A. Chowdhury, MD, PhD 

Badrul A. Chowdhury, MD, PhD 
Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma  B.Lauren Charous, MD, Elkan F. Halpern,

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma  B.Lauren Charous, MD, Elkan F. Halpern,
Pathophysiology of severe asthma

Pathophysiology of severe asthma
NAEPP Expert Panel Report

NAEPP Expert Panel Report
Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis  James.
Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia  Carol K. Fosso, MDa,

Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia  Carol K. Fosso, MDa,
Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W
Elinor Simons, MDa, William M

Elinor Simons, MDa, William M
Elephantiasis nostras: A case report

Elephantiasis nostras: A case report
Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial  William Busse, MDa,

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial  William Busse, MDa,

Similar presentations

Ads by Google